Divi's Lab Stock - Long-term growth story in Indian pharma
Published on 06/20/2026 at 15:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 15:05 CET. Details in the imprint.
Divi's Lab (INE361B01024) is one of India's most closely watched specialty pharma manufacturers. With no new filings or major headlines today, investors are revisiting the company's long-term earnings drivers and positioning in active pharmaceutical ingredients.
Background and price data on Divi's Lab
All news, filings and market data on Divi's Lab stock are collected on the ad-hoc-news topic page and the company's own investor relations site.
How Divi's Lab earns its money
Divi's Lab focuses on custom synthesis and generic active pharmaceutical ingredients (APIs) for global innovators and generic drug makers, with export-heavy revenue from regulated markets like the United States and Europe.
According to its public profile and exchange data, the company operates in the healthcare and pharmaceuticals space and is classified under pharmaceuticals and drugs on Indian stock platforms.
Long-term growth drivers in APIs
The structural case for Divi's Lab rests on continued outsourcing of complex chemistry to India, growing demand for specialty APIs and vitamins, and regulatory pressure on global pharma to secure diversified, compliant supply chains.
Market data providers list Divi's Lab within the healthcare sector, reflecting its role as a supplier to a broad set of global pharmaceutical customers rather than a consumer-brand drug maker.
What the company sells
Divi's Lab generates most of its revenue from custom synthesis projects and a portfolio of generic APIs and intermediates used in therapies such as antivirals, central nervous system drugs and vitamins, serving large global pharmaceutical companies.
Where the stock trades today
Shares of Divi's Lab (INE361B01024) last traded on the National Stock Exchange of India at around ?6,749.50 as of 06/20/2026, 06:05 IST.
Key facts on Divi's Lab stock
- Company: Divi's Laboratories Ltd
- ISIN: INE361B01024
- WKN: 532488
- Ticker: DIVISLAB
- Venue: NSE
- Price (as of 06/20/2026, 06:05 IST): 6,749.50 INR
- Market cap: 1,79,000.00 crore INR (as of 06/20/2026)
- Sector / Industry: Healthcare - Pharmaceuticals & Drugs
- Index membership: Nifty 50
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
